Moderna Boosts Production with Lonza Deal
Moderna Therapeutics (MRNA) announced its new collaboration with Lonza for boosting its production capacity for mRNA 1273. The company had recently struck a deal with the federal government to focus on developing COVID 19 vaccine candidate. The company stands to receive $483 million from BARDA for accelerating the development of the vaccine. Moderna dosed the first patient under its Phase I clinical trial in March.
Under the latest deal with the Swiss firm, Moderna will be able to use Lonza manufacturing facilities in the United States and